CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.

If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.

CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an ...

The average one-year price target for CRISPR Therapeutics (NasdaqGM:CRSP) has been revised to $82.91 / share. This is an increase of 14.61% from the prior estimate of $72.34 dated January 11, 2026.

CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory. The company ...

CRISPR Therapeutics CRSP is expected to report third-quarter 2025 earnings later this week. The Zacks Consensus Estimate for quarterly sales is pegged at $6.71 million, while that for earnings is ...

CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood’s Stock Portfolio is one of the top 10 stocks to buy now. On August 7, analysts at H.C. Wainwright reiterated a ‘Buy’ rating on the stock and raised ...

CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting continued clinical progress, expanding uptake of Casgevy, and momentum across its ...